Literature DB >> 16086909

Paclitaxel, cisplatin, 5-fluorouracil and radiotherapy in the management of advanced squamous cell carcinoma of the head and neck: a phase II trial.

Marco Merlano1, Elvio G Russi, Gianmauro Numico, Ida Colantonio, Ornella Garrone, Antonio Pelissero, Cristina Granetto, Milena Gasco, Gianna Di Costanzo, Abdelhamid Heouaine, Riccardo Vigna Taglianti, Marco Cipolat.   

Abstract

Aim of the present study was to test, activity and toxicity of a rapidly alternating chemoradiation (paclitaxel based) in 31 patients with unresectable, locally advanced or recurrent after surgery, head and neck cancer. Three-year overall survival and progression-free survival were 61.4 and 73.7%, respectively. Main side effects remain a major problem.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 16086909     DOI： 10.1016/j.radonc.2004.11.007

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN： 0167-8140            Impact factor:   6.280


  1 in total

1.  3D-conformal-intensity modulated radiotherapy with compensators for head and neck cancer: clinical results of normal tissue sparing.

Authors:  Thomas G Wendt; Nasrin Abbasi-Senger; Henning Salz; Ines Pinquart; Sven Koscielny; Susi-Marie Przetak; Tilo Wiezorek
Journal:  Radiat Oncol       Date:  2006-06-21       Impact factor: 3.481
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.